PAVmed
PAVM | NASDAQ
$1.75
+$0.12 (+7.36%)
At close: Nov 16, 2026, 4:00 PM ET
$1.72
-$0.03 (-1.71%)
After-hours:
Nov 16, 2026, 6:27 PM ET
+7.36%
(1D)No price chart data available for 1D timeframe.
Rating
35.8
+2.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #640/1021 (Top 63%)
Key Statistics
Market Data
Market Cap $13.99M
1D Range
1.57 2.29
52W Range
1.34 12.05
Valuation (TTM)
PE -0.19
PB 0.40
EV/EBITDA -1.60
Valuation (NTM)
Forward PE N/A
Forward PEG -0.31
Price Target $57.00
Cash Flow
FCF Yield -55.6%
SBC Adj. FCF Yield -67.9%
SBC Impact -22.0%
Margins
Gross Margin -158.8%
Operating Margin -19315.5%
FCF Margin -5258.1%
Growth (CAGR)
Revenue 3Y | 5Y -53.9% |
-5.8%
Dil EPS 3Y | 5Y 115.3% |
63.7%
FCF 3Y | 5Y 89.5% |
41.6%
Returns
ROA -49.1%
ROE -54.7%
ROIC -77.9%
Financial Health
Net Debt
$11.32M
Current Ratio 1.19
Interest Coverage -2,858.70
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings...
Sector Healthcare
Industry Medical - Devices
Employees 41
IPO Date Jul 27, 2016
Website www.pavmed.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 13, 2026
EPS
-$1.76
Miss -198.31%
YoY:
+79.77% REV
$41K
Beat +64.00%
YoY:
+720.00%Next Earnings
Mar 29, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$57.00
Upside
+3157.14%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PAVM